A Case Report of a Well-Differentiated Neuroendocrine Tumor in which Sunitinib Treatment Resulted an Effective Response of Disease Abstract #2157

Introduction: A case report of no pancreatic well-differentiated neuroendocrine tumor in which sunitinib treatment resulted an effective response of disease
Aim(s): A 24 year old man had a primary carcinoid tumor (NET 2) with multiple liver metastasis and ileal tumor, Since no drug were approved for NETS at that time in Algeria,
Materials and methods: We treated him after surgery of the primary and sandostatine LAR with sunitinib after approval by my head of my department of oncology and informed consent of the patient , Sunitinib was administered at daily dose of 37,5 mg/day with good tolerability since 2010 ,The non-hematological toxicity was hand and foot syndrome (G2) and controlled with topics and fatigue (G2 ) , CT revealed stable disease after 3 months of treatment for 36 months with safety profile than PR of liver metastasis with therapeutic windows sometimes . we preconize surgery in 6 of June 2014 and we obtain very good response and no liver lesion in the CT of April 2015 than we decided to maintain the patient under 25 mg of sunitinib because he had asthenia (G2 and sometimes G3)
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Case reports
Presenting Author: PH Radia Sai
Authors: SAI R

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2698 Safety and Efficacy of Salvage PRRT with 177Lu-DOTA-Octreotate in Patients with Well-Differentiated Metastatic Neuroendocrine Tumours (NET)
Introduction: Peptide receptor radionuclide therapy (PRRT) is an effective therapy in patients with a somatostatin receptor-positive neuroendocrine tumour (NET). NETTER-1 trial demonstrated high efficacy and low toxicity of four cycles.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Nariman Ghaleb
#2795 Molecular Correlation of the Activity of Evofosfamide (EVO) in Combination with Sunitinib (SUN) in Pancreatic Neuroendocrine Tumors (pNETs) in the SUNEVO GETNE Trial
Introduction: MEN1, DAXX, ATRX, and PI3K/AKT/mTOR pathway genes are frequently mutated in pNETs. Sunitinib is approved and widely used in the metastatic setting but unfortunately, no validated predictive biomarker has been identified to guide therapy yet. The SUNEVO phase II trial of the Spanish Task Force Group for Neuroendocrine and Endocrine Tumours (GETNE) trial combined the pro-drug of EVO under SUN-induced hypoxic conditions.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Trials in Progress/Trials in Concept
Presenting Author: Dr. Enrique Grande
#2869 Sunitinib in Combination with Lanreotide for the Treatment of Pancreatic Neuroendocrine Tumors
Introduction: A 33-year-old patient with pancreatic neuroendocrine tumor (NET) G2 revealed progression of the disease in the form of multiple metastases to the liver, lymph nodes of the hepatoduodenal ligament and retroperitoneal space 1.5 months after surgical treatment.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: Anna Kuznetsova
#2948 Efficacy Prediction Using Computed Tomography for Patients with Pancreatic Neuroendocrine Tumors Receiving Sunitinib
Introduction: How to predict the efficacy of sunitinib before treatment initiation was less known.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Imaging and Interventions (radiology, endoscopy)
Presenting Author: Professor Jie Chen
Authors: Zhang Y, Chen L, Wang W, Jin K, ...
#2949 Sunitinib May Be an Effective Treatment for Hypercalcemia Due To a Metastatic Pancreatic Neuroendocrine Tumor
Introduction: Malignant hypercalcemia due to neuroendocrine tumor(NET) is rare, and only a few reports are available in the literature.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: Prof. Huang-Ying Tan
Authors: Wang C, Qi Z, Tan H D, Tan H Y, ...